Klertis (Sunitinib)

Sunitinib blocks several receptor tyrosine kinases such as VEGFR, PDGFR, KIT, and FLT3. By inhibiting these receptors it reduces angiogenesis (new blood‑vessel formation) and directly suppresses cancer‑cell proliferation, leading to slowed tumor growth and potential tumor shrinkage.

The exact dose and schedule of Klertis are determined by the prescribing physician based on the specific cancer type, disease stage, patient weight, renal function, and tolerance. Healthcare professionals adjust the regimen to achieve the best therapeutic outcome while managing safety.

Sunitinib is classified as contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, so nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Klertis (sunitinib) shares the same class as drugs like pazopanib and sorafenib but differs in its kinase inhibition profile. Sunitinib uniquely targets KIT and FLT3 in addition to VEGFR and PDGFR, making it effective for gastrointestinal stromal tumors and certain neuroendocrine tumors where other agents may be less active.

Klertis should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight to maintain stability throughout the shelf life.

Klertis is taken orally, usually as a whole tablet swallowed with water. The prescribing physician will indicate whether the tablet should be taken with food or on an empty stomach, and will outline the treatment cycle (e.g., four weeks on, two weeks off) based on clinical guidelines.

Serious adverse events include cardiac dysfunction (reduced left‑ventricular ejection fraction), severe hypertension, liver toxicity, bleeding complications, thromboembolic events, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these conditions.

Klertis is contraindicated in patients with known hypersensitivity to sunitinib or any of its excipients. It should also be avoided in individuals with uncontrolled hypertension, recent major cardiovascular events, or severe hepatic impairment unless a specialist determines the benefits outweigh the risks.